浏览全部资源
扫码关注微信
奥拉帕利辅助治疗
BRCA1/2 突变HER2阴性乳腺癌有效性与安全性的Meta分析Efficacy and safety of olaparib in adjuvant therapy of
BRCA1/2 mutated HER2-negative breast cancer： a meta-analysis- 中国药房 2023年34卷第9期 页码：1109-1114
- 作者机构：
1.四川省肿瘤临床医学研究中心/四川省肿瘤医院研究所/四川省癌症防治中心/电子科技大学附属肿瘤医院药学部，成都 610041
2.哈尔滨医科大学附属肿瘤医院药学部，哈尔滨 150086
- 作者简介：
主管药师，博士。研究方向：肿瘤个体化药物治疗。电话：028-85420311。E-mail：cyfy1112@163.com
主管药师，博士。研究方向：肿瘤个体化药物治疗。电话：0451-86298399。E-mail：jdyhmu3@163.com
- 基金信息：四川省科技计划项目(2022NSFSC0792);成都市科技技术创新研发项目(2022-YF05-01591-SN);北京市希思科临床肿瘤学研究基金项目(Y-QL202101-0125);个体化药物治疗四川省重点实验室开放和自拟课题资助项目(2021YB03);中国药学会医院药学专委会医院药学科研专项资助项目(CPA-Z05-ZC-2022-002)
DOI：10.6039/j.issn.1001-0408.2023.09.16
中图分类号： R979.1纸质出版日期：2023-05-15，
收稿日期：2023-01-16，
修回日期：2023-02-08，
扫 描 看 全 文
陈燕,姜帅.奥拉帕利辅助治疗BRCA1/2突变HER2阴性乳腺癌有效性与安全性的Meta分析 Δ[J].中国药房,2023,34(09):1109-1114.
CHEN Yan,JIANG Shuai.Efficacy and safety of olaparib in adjuvant therapy of BRCA1/2 mutated HER2-negative breast cancer： a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(09):1109-1114.
陈燕,姜帅.奥拉帕利辅助治疗BRCA1/2突变HER2阴性乳腺癌有效性与安全性的Meta分析 Δ[J].中国药房,2023,34(09):1109-1114. DOI： 10.6039/j.issn.1001-0408.2023.09.16.
CHEN Yan,JIANG Shuai.Efficacy and safety of olaparib in adjuvant therapy of BRCA1/2 mutated HER2-negative breast cancer： a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(09):1109-1114. DOI： 10.6039/j.issn.1001-0408.2023.09.16.
摘要
目的
2
系统评价奥拉帕利辅助治疗乳腺癌易感基因（
BRCA
）
1/2
突变人表皮生长因子受体2（HER2）阴性乳腺癌的有效性和安全性，为临床治疗提供循证参考。
方法
2
计算机检索中国知网、维普、万方、PubMed、ScienceDirect、the Cochrane Library和Embase数据库，收集奥拉帕利辅助治疗（试验组）对比其他药物辅助治疗（对照组）的随机对照试验。筛选文献、提取数据后，采用RevMan 5.4软件进行Meta分析、发表偏倚分析和敏感性分析。
结果
2
共纳入5项随机对照试验，共计2 633例患者，其中试验组1 459例，对照组1 174例。Meta分析结显示，在有效性方面，与对照组相比，试验组患者的总生存期[HR＝1.02，95%CI（1.01，1.03），
P
＝0.000 8]和无进展生存期[HR＝1.78，95%CI（1.46，2.17），
P
＜0.000 01]显著延长。在安全性方面，与对照组相比，试验组患者的任何级别不良反应发生率更高[RR＝1.41，95%CI（1.12，1.78），
P
＝0.004]，而两组患者的3级以上不良反应发生率比较差异无统计学意义[RR＝1.75，95%CI（0.82，3.74），
P
＝0.15]。发表偏倚结果显示，本研究存在发表偏倚的可能性较小。敏感性分析结果显示，本研究所得结果稳健。
结论
2
与非奥拉帕利辅助治疗的患者相比，奥拉帕利辅助治疗
BRCA1/2
突变HER2阴性乳腺癌可延长患者的总生存期和无进展生存期，但不良反应发生风险相对较高。
Abstract
OBJECTIVE
2
To systematically evaluate the efficacy and safety of olaparib in adjuvant therapy of breast cancer susceptibility gene （
BRCA
）
1/2
mutated human epidermal growth factor receptor 2 （HER2）-negative breast cancer， and to provide evidence-based reference for clinical treatment.
METHODS
2
Retrieved from CNKI， VIP， Wanfang data， PubMed， ScienceDirect， the Cochrane Library and Embase databases， randomized controlled trials about adjuvant therapy of olaparib （trial group） versus adjuvant therapy of other drugs （control group） were collected. After literature screening and data extraction， meta-analysis， publication bias analysis and sensitivity analysis were performed by using RevMan5.4 software.
RESULTS
2
A total of 5 randomized controlled trials were included， with a total of 2 633 patients， including 1 495 cases in trial group and 1 174 cases in control group. Meta-analysis showed that in terms of efficacy， compared with control group， overall survival [HR＝1.02， 95%CI （1.01，1.03），
P
＝0.000 8] and progression-free survival [HR＝1.78， 95%CI（1.46，2.17），
P
＜0.000 01] were longer significantly in the trial group. In terms of safety， compared with the control group， the incidence of adverse drug reactions at any level in the trial group was higher [RR＝1.41， 95%CI （1.12， 1.78），
P
＝0.004]， while there was no statistically significant difference in the incidence of adverse drug reactions above level 3 between the two groups [RR＝1.75， 95%CI （0.82， 3.74），
P
＝0.15]. The results of publication bias indicated that the possibility of publication bias in this study was relatively low. The results of sensitivity analysis showed that the results obtained in this study were robust.
CONCLUSIONS
2
Compared with patients without adjuvant therapy of olaparib， adjuvant therapy of olaparib can prolong overall survival and progression-free survival of patients with
BRCA1/2
mutated HER2-negative breast cancer， but the risk of adverse drug reactions is relatively high.
关键词
奥拉帕利乳腺癌易感基因人表皮生长因子受体2乳腺癌有效性安全性
Keywords
breast cancer susceptibility genehuman epidermal growth factor receptor 2breast cancerefficacysafety
references
Breast Cancer Association Consortium，DORLING L，CARVALHO S，et al. Breast cancer risk genes-association analysis in more than 113 000 women[J]. N Engl J Med，2021，384（5）：428-439.
KUCHENBAECKER K B，HOPPER J L，BARNES D R，et al. Risks of breast，ovarian，and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA，2017，317（23）：2402-2416.
KAUFMAN B，SHAPIRA-FROMMER R，SCHMUTZLER R K，et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J]. J Clin Oncol，2015，33（3）：244-250.
SLADE D. PARP and PARG inhibitors in cancer treatment[J]. Genes Dev，2020，34（5/6）：360-394.
HELLEDAY T. The underlying mechanism for the PARP and BRCA synthetic lethality：clearing up the misunderstandings[J]. Mol Oncol，2011，5（4）：387-393.
GAN Y，LI L Q，ZHANG L W，et al. Association between shift work and risk of prostate cancer：a systematic review and meta-analysis of observational studies[J]. Carcinoge- nesis，2018，39（2）：87-97.
TUTT A N J，GARBER J E，KAUFMAN B，et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med，2021，384（25）：2394-2405.
ROBSON M，IM S A，SENKUS E，et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med，2017，377（6）：523-533.
IM S A，XU B H，LI W，et al. Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer：OlympiAD randomized trial subgroup analysis[J]. Sci Rep，2020，10（1）：8753.
ROBSON M E，TUNG N，CONTE P，et al. OlympiAD final overall survival and tolerability results：Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol，2019，30（4）：558-566.
FASCHING P A，LINK T，HAUKE J，et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency （GeparOLA study）[J]. Ann Oncol，2021，32（1）：49-57.
FELICIO P S，GRASEL R S，CAMPACCI N，et al. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer[J]. Hum Mutat，2021，42（3）：290-299.
LI S，SILVESTRI V，LESLIE G，et al. Cancer risks asso- ciated with BRCA1 and BRCA2 pathogenic variants[J]. J Clin Oncol，2022，40（14）：1529-1541.
MOMOZAWA Y，SASAI，USUI Y，et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants[J]. JAMA Oncol，2022，8（6）：871-878.
LEE A，MOON B I，KIM T H. BRCA1/BRCA2 pathogenic variant breast cancer：treatment and prevention stra- tegies[J]. Ann Lab Med，2020，40（2）：114-121.
FOO T K，XIA B. BRCA1-dependent and independent recruitment of PALB2-BRCA2-RAD51 in the DNA damage response and cancer[J]. Cancer Res，2022，82（18）：3191-3197.
FU X Y，TAN W，SONG Q B，et al. BRCA1 and breast cancer：molecular mechanisms and therapeutic strategies[J]. Front Cell Dev Biol，2022，10：813457.
ZHUANG J J，CHEN P，WU Y H，et al. Brca1 is regulated by the transcription factor Gata3，and its silencing promotes neural differentiation in retinal neurons[J]. Int J Mol Sci，2022，23（22）：13860.
CREMONA M，VANDENBERG C J，FARRELLY A M，et al. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis （IAP） family inhibitors[J]. Br J Cancer，2022，127（3）：488-499.
VARKHEDI M，BARKER V R，EAKINS R A，et al. CNV assessments associated with outcome distinctions for adult and pediatric cancers：loss of BRCA1 in neuroblastoma associates with a lower survival probability[J]. Gene，2022，836：146673.
WANG Y，MA B B，LIU X X，et al. ZFP281-BRCA2 prevents R-loop accumulation during DNA replication[J]. Nat Commun，2022，13（1）：3493.
EDAILY S，ABDEL-RAZEQ H. Management strategies of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants[J]. Onco Targets Ther，2022，15：815-826.
YU J，ZHANG C，SHI W，et al. BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system[J]. Clin Transl Oncol，2022，24（5）：919-926.
GUPTA T，VINAYAK S，TELLI M. Emerging strategies：PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer[J]. Breast Cancer Res Treat，2023，197（1）：51-56.
LUO L J，KEYOMARSI K. PARP inhibitors as single agents and in combination therapy：the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers[J]. Expert Opin Investig Drugs，2022，31（6）：607-631.
WANG Q W，BERGHOLZ J S，DING L Y，et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer[J]. Nat Commun，2022，13（1）：3022.
MENEZES M C S，RAHEEM F，MINA，et al. PARP inhibitors for breast cancer：germline BRCA1/2 and beyond[J]. Cancers （Basel），2022，14（17）：4332.
LAU C H，SEOW K M，CHEN K H. The molecular mechanisms of actions，effects，and clinical implications of PARP inhibitors in epithelial ovarian cancers：a syste- matic review[J]. Int J Mol Sci，2022，23（15）：8125.
WANG Y J，LUO W B，WANG Y F. PARP-1 and its associated nucleases in DNA damage response[J]. DNA Repair （Amst），2019，81：102651.
WILSON Z，ODEDRA R，WALLEZ Y，et al. ATR inhibitor AZD6738 （ceralasertib） exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib[J]. Cancer Res，2022，82（6）：1140-1152.
KIM D，NAM H J. PARP inhibitors：clinical limitations and recent attempts to overcome them[J]. Int J Mol Sci，2022，23（15）：8412.
0
浏览量
6
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 地址：重庆市渝中区大坪正街129号四环大厦8层 400042
- 技术支持由北京北大方正电子有限公司提供 渝ICP备15012710号
公网安备50010302001817 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies